Underscoring the lucrative potential for biosimilars, Pfizer (PFE) has accused Johnson & Johnson (JNJ) of using anti-competitive practices to prevent insurers from covering its version of a best-selling J&J medicine.

In a lawsuit filed on Wednesday, Pfizer claims that J&J used various illegal contracting tactics to convince insurers not to cover Inflectra, a biosimilar version of the blockbuster Remicade treatment for rheumatoid arthritis and other diseases. A biosimilar, you may recall, is a nearly identical variant of a brand-name biologic medicine and is expected to provide the same result in patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If memory serves, J&J outright sued then Abbott and won $1.7 billion USD for infringement on the Remicade patent by the Humira product, It was overturned on appeal but still rather worse tactics than just low sales, I think.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy